Early research (Phase 1)Study completedNCT02338349
What this trial is testing
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
Who this might be right for
Advanced ER+, HER2-Negative Breast Cancer
Stemline Therapeutics, Inc. 57